GetTopicDetailResponse(id=44369e6246d, topicName=陣發(fā)性叢集性頭痛, introduction=陣發(fā)性叢集性頭痛, content=null, image=null, comments=4, allHits=1050, url=https://h5.medsci.cn/topic?id=97624, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=90696, tagList=[TagDto(tagId=90696, tagName=陣發(fā)性叢集性頭痛)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2055320, encodeId=4142205532054, content=<a href='/topic/show?id=44369e6246d' target=_blank style='color:#2F92EE;'>#陣發(fā)性叢集性頭痛#</a>, objectTitle=Lancet Neurology：潑尼松與安慰劑短期預(yù)防陣發(fā)性叢集性頭痛的安全性和有效性：一項(xiàng)多中心、雙盲、隨機(jī)對(duì)照試驗(yàn) , objectType=article, longId=205525, objectId=370820552554, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=370820552554, replyNumber=0, likeNumber=0, createdTime=2021-10-27, rootId=0, userName=12498f17m66暫無昵稱, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=370820552554, moduleTitle=Lancet Neurology：潑尼松與安慰劑短期預(yù)防陣發(fā)性叢集性頭痛的安全性和有效性：一項(xiàng)多中心、雙盲、隨機(jī)對(duì)照試驗(yàn) , moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=370820552554)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2055321, encodeId=8b122055321f0, content=<a href='/topic/show?id=44369e6246d' target=_blank style='color:#2F92EE;'>#陣發(fā)性叢集性頭痛#</a>, objectTitle=Emgality（galcanezumab）治療陣發(fā)性叢集性頭痛：已在加拿大獲得批準(zhǔn), objectType=article, longId=207661, objectId=8a1820e661cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a1820e661cb, replyNumber=0, likeNumber=130, createdTime=2021-11-24, rootId=0, userName=12498f17m66暫無昵稱, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a1820e661cb, moduleTitle=Emgality（galcanezumab）治療陣發(fā)性叢集性頭痛：已在加拿大獲得批準(zhǔn), moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=8a1820e661cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2055319, encodeId=267e2055319d2, content=<a href='/topic/show?id=44369e6246d' target=_blank style='color:#2F92EE;'>#陣發(fā)性叢集性頭痛#</a>, objectTitle=NEJM：Galcanezumab預(yù)防陣發(fā)性叢集性頭痛, objectType=article, longId=175198, objectId=b0c41e5198a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0c41e5198a7, replyNumber=0, likeNumber=96, createdTime=2019-07-12, rootId=0, userName=12498f17m66暫無昵稱, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0c41e5198a7, moduleTitle=NEJM：Galcanezumab預(yù)防陣發(fā)性叢集性頭痛, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=b0c41e5198a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2055318, encodeId=362e20553184f, content=<a href='/topic/show?id=44369e6246d' target=_blank style='color:#2F92EE;'>#陣發(fā)性叢集性頭痛#</a>, objectTitle=禮來的CGRP抑制劑Emgality喜獲FDA批準(zhǔn)，成為陣發(fā)性叢集性頭痛的治療藥物, objectType=article, longId=167749, objectId=2b1416e7498d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b1416e7498d, replyNumber=0, likeNumber=81, createdTime=2020-02-02, rootId=0, userName=12498f17m66暫無昵稱, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b1416e7498d, moduleTitle=禮來的CGRP抑制劑Emgality喜獲FDA批準(zhǔn)，成為陣發(fā)性叢集性頭痛的治療藥物, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=2b1416e7498d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
